Football star Cristiano Ronaldo has invested in Bioniq, a personalised supplementation and health optimisation firm, boosting its valuation to $82m.

Bioniq, founded in 2019, offers personalised nutrition support based on blood biomarker data.

According to the company, Ronaldo has been Bioniq’s member since 2022 and uses its personalised supplements to enhance his health and performance.

The investment highlights the growing importance of vitamins, minerals, and supplements for athletes and consumers alike, Bioniq said.

Ronaldo will also be involved in future brand and product innovations.

The firm’s user base has expanded in 2024, and its products are being sold in over 70 countries. Bioniq’s approach is supported by scientists and a patent-pending algorithm.

By combining blood biomarker analysis with self-reported health data, it offers fully customised supplements. This platform creates a formula for each user, aiming to meet individual health needs, optimise nutrition over time, and advance personal health management.

The precision platform creates a daily formula for each user, meeting foundational nutrition needs and optimising nutrient levels over time.

Ronaldo said: “With their personalised health approach, I believe Bioniq has the potential to transform how we care for our bodies and help people reach and maintain their peak performance for longer.”

The investment will help the supplement firm in boosting its global expansion, particularly in the US, Europe, and the Middle East.

It will also enhance Bioniq’s personalised health solutions, delivering precision nutrition and empowering optimal health outcomes.

The health optimisation firm partners with health and sports institutions like Lanserhof and UFC. It has also collaborated with Soccer World Cup Champions, NBA All-Stars, and Iron Man winners.

Bioniq co-founder and CEO Vadim Fedotov said: “As the ultimate embodiment of performance and longevity, Cristiano fully aligns with the values and mission of Bioniq.”

Ronaldo’s investment follows a successful Series B, raising $15m led by HV Capital and Unbound, two European venture capitalists (VCs).

Bioniq has created a proprietary biochemical database, using blood test data from customers worldwide.

The artificial intelligence (AI)-powered, patent-pending algorithm analyses individual factors to identify micronutrient imbalances and provide tailored nutritional insights, daily support, and consultations.

Its products are Swiss-made and pharmaceutical-grade, utilising micro-dosing to meet individual needs.

Each formula includes a blend of up to 120 antioxidants, vitamins, minerals, phytonutrients, amino acids, and prebiotic fibre.